Tobacco company Altria (NYSE: MO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 14.5% year on year to $5.85 billion. Its non-GAAP profit of $1.30 per share was 1.3% below analysts’ consensus estimates.
Is now the time to buy MO? Find out in our full research report (it’s free for active Edge members).
Altria (MO) Q4 CY2025 Highlights:
- Revenue: $5.85 billion vs analyst estimates of $5.01 billion (14.5% year-on-year growth, 16.6% beat)
- Adjusted EPS: $1.30 vs analyst expectations of $1.32 (1.3% miss)
- Adjusted EBITDA: $2.96 billion vs analyst estimates of $3.09 billion (50.6% margin, 4.4% miss)
- Adjusted EPS guidance for the upcoming financial year 2026 is $5.64 at the midpoint, beating analyst estimates by 0.9%
- Operating Margin: 50%, down from 56.4% in the same quarter last year
- Market Capitalization: $100.3 billion
StockStory’s Take
Altria’s fourth quarter results drew a negative market reaction, largely due to a pronounced decline in operating margin despite surpassing sales expectations. Management pointed to increased investments in manufacturing capabilities and ongoing pressure from illicit e-vapor products as key factors impacting profitability. CEO Billy Gifford noted that, while the company achieved meaningful milestones in its smoke-free portfolio, “the proliferation of illicit flavored disposable e-vapor products evading regulatory process… jeopardizes the long-term tobacco harm reduction opportunity.”
Looking ahead, Altria’s forward guidance is anchored by plans for a national rollout of ON PLUS nicotine pouches and continued investment in manufacturing infrastructure to support both traditional and smoke-free products. Management expects growth to be weighted toward the second half of the year, with CFO Salvatore Mancuso highlighting that “planned investments to support our contract manufacturing capabilities” and a measured approach to e-vapor spending will affect the timing of profit improvements. The company is also closely monitoring regulatory progress and enforcement actions that could shape future category trends.
Key Insights from Management’s Remarks
Management attributed the quarter’s revenue growth to resilient core brands, expansion in the oral nicotine category, and strategic investments in manufacturing and product innovation amid regulatory challenges.
- Illicit e-vapor headwinds: The continued presence of illicit flavored disposable e-vapor products weighed on cigarette volume and profitability, with management emphasizing that enforcement actions have yet to meaningfully reduce this impact.
- ON PLUS progress: Altria received FDA authorization for ON PLUS in several flavors and began shipments in select states, positioning the product for a national launch in the first half of next year. Early consumer feedback praised pouch comfort and flavor, supporting its premium positioning.
- Basic brand repositioning: The company expanded its Basic discount cigarette offering to over 30,000 stores, targeting price-sensitive consumers facing economic pressure. Management described this as a data-driven move to retain value-conscious smokers and minimize share loss to deep discount brands.
- Manufacturing investments: Elevated manufacturing costs were driven by capital outlays to enhance import and export capabilities, a move intended to support future international expansion and unlock tax efficiencies through duty drawback benefits.
- Competitive pricing in pouches: Competitor promotional activity in nicotine pouches intensified, leading to lower average retail prices across the category. Despite this, Altria maintained pricing discipline for ON, focusing on profitability and brand loyalty.
Drivers of Future Performance
Altria’s outlook for the next year hinges on national smoke-free product expansion, manufacturing upgrades, and evolving regulatory enforcement.
- National ON PLUS launch: The rollout of ON PLUS nicotine pouches nationwide is expected to drive segment growth. Management aims to balance consumer trial and retention through product innovation and targeted retail investment, despite aggressive competitor promotions.
- Import-export efficiency gains: Ongoing capital investments in manufacturing are intended to unlock duty drawback tax benefits and enhance flexibility for international sales. Management sees a strong payback on these investments, though upfront costs will pressure margins in the near term.
- Regulatory and enforcement landscape: Altria is closely watching FDA actions and federal enforcement against illicit e-vapor products. The company believes regulatory progress could shift competitive dynamics and improve the operating environment for authorized smoke-free products.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will be monitoring (1) the pace and consumer adoption of a national ON PLUS launch, (2) progress toward realizing import-export tax efficiencies and related margin stabilization, and (3) regulatory enforcement developments targeting illicit e-vapor products. The trajectory of manufacturing investments and the ability to sustain premium pricing in nicotine pouches will also be critical signposts for Altria’s progress.
Altria currently trades at $59.82, down from $63.13 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
